Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall

During Regeneron's (NASDAQ:REGN) earnings call on Tuesday, Chief Scientific Officer George Yancopoulos told analysts that the company planned to start human trials of REGN-COV2, the company's experimental COVID-19 treatment, in June. That means that if results from those studies are positive, the antibody cocktail could be available for use by the end of summer or fall.